Freenome Inc (FRNM)

Currency in USD
9.82
-0.27(-2.68%)
Closed·
9.83+0.01(+0.10%)
·
FRNM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.7410.56
52 wk Range
9.7117.50
Key Statistics
Prev. Close
9.82
Open
10.2
Day's Range
9.74-10.56
52 wk Range
9.71-17.5
Volume
528.51K
Average Volume (3m)
843.54K
1-Year Change
-8.6512%
Book Value / Share
4.48
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
FRNM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
18.00
Upside
+83.30%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Freenome Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 18.00
(+83.30% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BTIG
Buy17.00+73.12%-Maintain11-11-2026
Guggenheim
Buy21.00+113.85%-New Coverage20-08-2026
TD Cowen
Buy17.00+73.12%-New Coverage18-08-2026
BTIG
Buy17.00+73.12%-New Coverage17-08-2026
Jefferies
Buy17.00+73.12%-New Coverage17-08-2026

Freenome Inc Earnings Call Summary for Q3/2026

  • Q3 revenue surged to $183.5M from $1M year-over-year, driven by $180M FDA approval milestone payment for SimpleScreen CRC test.
  • Company swung to profit with $0.58 diluted EPS vs. $0.95 loss prior year; ended quarter with $430M cash, funding operations into 2028.
  • Abbott launched SimpleScreen CRC Sept. 30; over 2,000 clinical sites requested kits in first 30 days with 800-person sales force deployed.
  • Q4 2026 revenue guided at $2M-$4M; full-year forecast $192M-$194M. Expects $70M milestone payment upon CRC v2 approval in H2 2027.
  • Pipeline catalysts include December single-cancer readouts, Q2 2027 multi-cancer data, and CRC version 2 supplemental PMA filing by year-end.
Last Updated: 11-11-2026, 04:04 am
Read Full Transcript

Earnings

Latest Release
11-11-2026
EPS / Forecast
0.58 / --
Revenue / Forecast
183.5M / --
EPS Revisions
Last 90 days

FRNM Income Statement

Compare FRNM to Peers and Sector

Metrics to compare
FRNM
Peers
Sector
Relationship
P/E Ratio
−9.5x−21.7x−0.2x
PEG Ratio
−0.15−2.230.00
Price/Book
2.2x3.0x2.6x
Price / LTM Sales
4.8x15.2x2.7x
Upside (Analyst Target)
83.3%14.3%68.5%
Fair Value Upside
Unlock−26.2%11.5%Unlock

Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen™ CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
10.37M9.65%104.64M
Other Institutional Investors
84.11M78.28%848.68M
Public Companies & Retail Investors
12.97M12.07%130.82M
Total
107.45M100.00%1.08B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Roche Holding AG17.40%1,86,92,7661,88,610
RA Capital Management, L.P.14.30%1,53,67,2701,55,056

FAQ

What Is the Freenome (FRNM) Share Price Today?

The Freenome share price today is 9.82.

What is the current Freenome (FRNM) share price and day range?

As of 18-11-2026, the Freenome share price is 9.82, with a previous close of 9.82. The share price has ranged from 9.74 to 10.56 today, while the 52-week range spans from 9.71 to 17.50.

What Is the Freenome Market Cap?

As of today, Freenome market cap is 1.06B.

What Is the Freenome (FRNM) Share Price Target?

The average 12-month share price target for Freenome is 18.00, with a high estimate of 21 and a low estimate of 17. 5 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +83.30% Upside potential.

What Is Freenome's Earnings Per Share (TTM)?

The Freenome EPS (TTM) is -3.19.

From a Technical Analysis Perspective, Is FRNM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

What Stock Exchange Does Freenome Trade On?

Freenome is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Freenome?

The stock symbol for Freenome is "FRNM."

How Many Times Has Freenome Stock Split?

Freenome has split 0 times.

How Many Employees Does Freenome Have?

Freenome has 363 employees.

What Is the FRNM Premarket Price?

FRNM's last pre-market stock price is 10.30. The pre-market share volume is 290.00, and the stock has changed by 0.21, or 2.08%.

What Is the FRNM After Hours Price?

FRNM's last after hours stock price is 9.83, the stock has changed by 0.01, or 0.10%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.